In our study, combined use of Melatonin with Neratinib led to potent inhibitory anti-tumor activities with no overt mouse body weight changes, supporting the potential of Melatonin as a combination adjuvant in the treatment of HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.